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Counteracting Effects of Cellular Notch and Epstein-Barr Virus
EBNA2: Implications for Stromal Effects on Virus-Host Interactions
Martin Rowe, Sweta Raithatha, Claire Shannon-Lowe
School of Cancer Sciences, The University of Birmingham, Birmingham, United Kingdom
ABSTRACT
A number of diverse environmental cues have been linked to B lymphocyte differentiation and activation. One such cue,
Notch-2, may be particularly relevant to the biology of infection with Epstein-Barr virus (EBV), which colonizes the B cell com-
partment. Activated Notch and EBV nuclear antigen 2 (EBNA2) both function as transcriptional activators by virtue of their in-
teractions with the transcription factor RBP-J. Although EBNA2 and activated Notch appear to have partially overlapping
functions, we now report that activated Notch counteracts a crucial EBNA2 function both in newly infected primary B cells and
in lymphoblastoid cell lines (LCLs). EBNA2 is directly responsible for the initiation of transcription of the majority of EBV pro-
teins associated with type III latency, leading to the outgrowth of LCLs. One of the key proteins driving this outgrowth is latent
membrane protein 1 (LMP1), which is regulated by an EBNA2-responsive element within its ED-L1 promoter. Activation of
Notch-2 via Delta-like ligand 1 inhibits EBNA2-mediated initiation of LMP1 transcription. Furthermore, ligated Notch-2 also
efficiently turns off LMP1 expression from the ED-L1 promoter in LCLs already expressing LMP1. Modulation of EBV gene ex-
pression by Notch was not confined to EBNA2-dependent events. Activated Notch-2 also inhibited EBV entry into the lytic cycle
in a B cell non-Hodgkin’s lymphoma line by upregulating the cellular transcription factor Zeb2, which represses the transcrip-
tion of BZLF1. These results support the concept that in vivo, cumulative signals from the microenvironment downregulate EBV
gene expression in B cells to the latency 0 gene expression profile observed in B cells entering the peripheral blood.
IMPORTANCE
Experimental infection of resting B cells by Epstein-Barr virus leads to the growth transformation program of virus gene expres-
sion and the outgrowth of lymphoblastoid cell lines. Previous studies at the single-cell level revealed complex cellular and viral
signaling networks regulating transcription of the viral genome. This study demonstrates that viral gene expression can also be
radically altered by molecules expressed on stromal cells in the microenvironment of lymphoid tissue, specifically, Delta-like
ligand 1 on stromal cells ligating Notch-2 on infected B cells. Activation of Notch interferes with the transactivation function of
EBNA2, downregulates the expression of LMP1 and LMP2a, and inhibits the activation of lytic virus replication in a B cell non-
Hodgkin’s lymphoma line by preventing expression of BZLF1. The significance of these observations is that they indicate new
mechanisms whereby the microenvironment in normal lymphoid tissue may facilitate the repression of viral gene expression,
enabling establishment of true latency in memory B cells.
The Notch pathway is an evolutionarily conserved intercellularsignaling pathway that transduces signals between adjacent
cells and plays an essential role in cell fate determination during
development, tissue homeostasis, and stem cell maintenance (1).
The intercellular signaling is mediated by four conserved recep-
tors (Notch 1 to 4) and two conserved families of Notch ligands
(Delta-like and Jagged), located on the plasma membrane. Acti-
vation of Notch receptors on the cell surface requires direct con-
tact between the extracellular domain of a Notch receptor with
one of the Notch ligands expressed on an adjacent cell. Notch
ligation triggers a regulated sequence of proteolytic cleavages (2,
3) which releases the intracellular Notch (ICN) fragment to trans-
locate to the nucleus, interact with the DNA binding protein RBP-
J, and function as a transcriptional activator (4–6).
Notch signaling events have been extensively studied during T
lymphopoiesis, where they play a crucial role during both early
development and differentiation into discrete effector cell com-
partments (7, 8). Notch is also implicated in regulation of multiple
stages of B cell development. It is now evident that Notch signaling
is crucial to generate the marginal zone B cell compartment lo-
cated within the spleen (9–11), and there is compelling evidence
that Notch may help shape the antibody repertoire (12). The gene
for Notch-2 is the primary Notch gene expressed by peripheral B
cells and predominantly interacts with Delta-like ligand 1 (DLL1)
(9–11).
Epstein-Barr virus (EBV), which is carried by the vast majority
of all adults worldwide, establishes a lifelong persistent infection
through colonizing the B lymphocyte compartment as a latent
infection. It has been postulated (13) that EBV exploits the normal
physiology of B cell differentiation to regulate its own gene expres-
sion. In addition to sharing a general feature of all herpesviruses,
which is the ability to expand the virus-infected cell pool by peri-
odic lytic replication to generate new infectious virions, EBV ad-
ditionally has the potential to expand the pool of virus-infected
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cells through growth transformation of B lymphocytes. In vitro,
this property is manifest following infection of purified resting B
cells, which results in the establishment of continuously prolifer-
ating lymphoblastoid cell lines (LCLs). B cell infection follows a
highly regulated cascade of viral gene expression, starting with
expression of the Epstein-Barr virus nuclear antigens (EBNAs)
EBNA2 and EBNA-LP (14). EBNA2 plays a pivotal role in B cell
infection through activating the transcription of almost all the
viral genes that are expressed during the growth transformation of
B cells, notably, the viral latent membrane proteins (LMPs) LMP1,
LMP2A, and LMP2B (15, 16), and the C promoter (Cp)-driven
expression of the nuclear antigens EBNA1, EBNA3A, EBNA3B,
and EBNA3C (17, 18). EBNA2 cannot bind to the viral DNA itself
to activate gene expression but interacts with RBP-J (19–21),
which tethers EBNA2 to EBNA2 response elements within pro-
moter regions of DNA. EBNA2 also activates the transcription of
cellular genes, including CD23, MYC, and CCR7 (21, 22).
Given that both ICN (intracellular or activated Notch) and
EBNA2 function as transcriptional activators by virtue of their
interaction with RBP-J, EBNA2 could be regarded as a functional
homologue of an active Notch receptor, albeit EBNA2 is constitu-
tively active and functions independently of a cell surface ligand
(23–25). In EBNA2-negative Burkitt lymphoma (BL) cell lines,
mouse ICN-1 is able to upregulate some EBNA2 viral targets, in-
cluding LMP2A, although not others, such as LMP1. Similarly,
ICN-1 is able to upregulate the EBNA2 cellular target CD21 but
not CD23. Additionally, both ICN-1 and EBNA2 downregulate
immunoglobulin M (IgM) expression, indicating that Notch has
both positive and negative regulatory functions. However, analy-
sis of the effect of ICN-1, ICN-2, and EBNA2 expression on ge-
nome-wide transcription in EBV-infected B cell lines revealed
profound differences in the regulation of target genes, with only a
small cluster of genes being concordantly regulated (26). EBNA2
appears to be more efficient in upregulating genes involved in
proliferation, survival, and chemotaxis, whereas ICN-1 and
ICN-2 are more potent at inducing genes associated with devel-
opment and differentiation.
Although it is now known that EBNA2 and Notch regulate
largely nonoverlapping gene sets, it is not yet clear to what extent
Notch might modulate EBV infection. This is a fundamental ques-
tion that is relevant for understanding virus persistence in vivo,
where virus-infected cells are exposed to intercellular signaling
molecules within stromal cell microenvironments.
In the present report, we examine how Notch ligation, via in-
teraction with stromal cells producing the Notch ligand Delta-like
ligand 1, regulates EBV gene expression in both latent and lytic
infection of B cells. We show that Notch signaling modulates la-
tent viral gene expression, most notably by inhibiting EBNA2-
dependent expression of LMP1, and can block entry into the lytic
cycle via an EBNA2-independent Zeb2-mediated block of BZLF1
expression.
MATERIALS AND METHODS
Ethics. Ethical approval for the use of primary B cells and bone marrow
was granted by the Solihull Local Research Ethics Committee (06/
Q2706/71) and the South Birmingham Research Ethics Committee
(07/H128/62).
Cells and cell lines. Primary B cells were isolated from peripheral
blood using CD19 Dynabeads and CD19 Detachabeads (Invitrogen), as
previously described (27).
Cultures of mouse thymic stromal cells (OP9) expressing the human
Delta-like ligand 1 (OP9-DLL1 cells) or control green fluorescent protein
(GFP; OP9-GFP cells) (kindly provided by Graham Anderson, The Uni-
versity of Birmingham) were maintained for up to 20 passages in Opti-
MEM medium (Gibco, Life Technologies) with 20% fetal calf serum
(FCS).
BNHL-1 cells were derived from a bone marrow sample from a patient
being treated for low-grade B cell non-Hodgkin’s lymphoma (NHL). Cells
of the BNHL-1 cell line were phenotypically the same as cells of the low-
grade B cell NHL observed in the patient. These cells were infected with
EBV and were continually maintained on the OP9-DLL1 cells, unless
specified otherwise. An EBV-negative counterpart was maintained in the
same manner.
293 cells containing recombinant wild-type EBV strain 2089 were
maintained in RPMI, 10% FCS, and 100 g/ml hygromycin. Akata cells
containing recombinant wild-type EBV Akata were maintained in RPMI,
10% FCS, and 50 ng/ml G418.
Virus preparations and infection experiments. Preparations of re-
combinant wild-type EBV Akata with a GFP insert (28) were generated by
inducing the virus producer B cell line with 0.1% goat anti-human poly-
clonal IgG (MP Biomedicals). Preparations of recombinant wild-type
EBV 2089 with a GFP insert (29) were made from 293 cells carrying the
recombinant EBV B95.8 genome, as previously described (27). Encapsi-
dated and enveloped virus was purified from the culture supernatants by
centrifugation on an OptiPrep (Axis Shield) self-generated gradient (30)
and quantitated by quantitative PCR (qPCR) of a single-copy gene,
BALF5, as previously described (27). The multiplicity of infection (MOI)
of the virus used in infection experiments was defined as the number of
EBV genomes in the purified virus preparations divided by the number of
target cells in culture.
EBV infection of primary B cells isolated from peripheral blood was
carried out at an MOI of 50, as described previously (27).
qRT-PCR for EBV and cellular transcripts. Total RNA was isolated
from cells using a NucleoSpin II RNA purification kit (Macherey-Nagel)
according to the manufacturer’s instructions. One microgram of RNA
was further digested with DNase (DNA-free; Ambion) according to the
manufacturer’s instructions. For quantitative real-time PCR (qRT-PCR)
of EBV and cellular transcripts, 400 ng of RNA was reverse transcribed in
a 20-l reaction volume using qScript cDNA SuperMix (Quanta-Biosci-
ences) according to the manufacturer’s instructions.
Quantitative RT-PCRs for EBV transcripts were performed using
EBV gene-specific primers as previously reported (31). Briefly, 20 ng of
cDNA was added to each qRT-PCR mixture to quantify W promoter
(Wp)- and C promoter (Cp)-initiated EBNA mRNAs; Y-U-K-spliced
EBNA1 mRNA; Q promoter (Qp)-initiated Q-U-K-spliced EBNA1
mRNA; and LMP1, LMP2a, BZLF1, and gp350 mRNAs.
Absolute quantitation of LMP1 and LMP2a transcripts was performed
using primers for total LMP1 (31) and for LMP1 originating from the
promoter (LT-R1) located in the terminal repeats (TRs): primer LMP1
(5=-CGTAGCCGCCCTACATAAGC; in the terminal repeats), primer
LMP1 (3=-CCCCTCTCAAGGTCGTGTTC; in exon 1), and the LMP1
probe (CCTCAGGGCAGTGTGTCAGGAGCA; in exon 1). A plasmid
construct containing the relevant amplicons for total LMP1, LMP1 de-
rived from the LT-R1 promoter, and beta-2-microglubulin (B2M) of
known copy number was diluted to give a standard curve from 105 copies
down to 1 copy in 10-fold dilutions. The standards and samples were
amplified (as reported previously 31), and the number of LMP1 tran-
scripts per cell was determined.
Relative quantitative RT-PCRs for cellular transcripts were performed
using TaqMan assays for each mRNA transcript (Life Technologies).
Briefly, 20 ng of cDNA was added to each qRT-PCR mixture to quantify
Oct-1, Oct-2, Zeb1, Zeb2, MYC, and PU.1. Each qRT-PCR assay was
performed by determination of the level of expression relative to that in a
suitable reference cell line, for which the result was given an arbitrary
value of 1, and then the level of expression was normalized against the level
Rowe et al.
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of expression of the B2M housekeeping gene. Oct-1 expression was deter-
mined relative to that in Jurkat cells, Oct-2 expression was determined
relative to that in Ramos cells, Zeb1 expression was determined relative to
that in Jurkat cells, and Zeb2 expression was determined relative to that in
HeLa cells, as suggested by the antibody manufacturer.
Detection of EBV and cellular proteins by immunofluorescence.
EBV-infected cells were fixed in 4% paraformaldehyde for 20 min at room
temperature and centrifuged onto poly-L-lysine-coated slides (Sigma) us-
ing a Shannon cytospin apparatus. The cells were permeabilized in 0.5%
Triton X-100 and stained for the EBV proteins EBNA1 (monoclonal an-
tibody R4; a kind gift from Laurie Frappier), BZLF1 (monoclonal anti-
body BZ.1 [32]), EBNA2 (monoclonal antibody PE2 [33]), LMP1 (mono-
clonal antibody CS.1-4 [34]), gp350 (monoclonal antibody 72A1 [35]),
and viral capsid antigen (VCA; Chemicon). All nonconjugated primary
antibodies were detected with the anti-mouse or anti-rabbit secondary
antibodies, as appropriate, labeled with Alexa Fluor 488 or 594 (Life Tech-
nologies).
Western blot analysis. Cells were lysed in urea buffer (9 M urea, 50
mM Tris, pH 7.5), sonicated, and quantitated against bovine serum albu-
min standards using a Bio-Rad DC protein assay. The cell lysates were
diluted in sample buffer to give a final concentration of 1 mg/ml protein in
2% sodium dodecyl sulfate (SDS), 62.5 mM Tris-HCl, pH 6.8, 10% glyc-
erol, 0.2 M sodium 2-mercaptoethanesulfonate, 0.002% bromophenol
blue and then heated to 100°C for 5 min. Solubilized proteins were sepa-
rated by SDS-electrophoresis on 4 to 12% gradient bis-Tris NuPAGE
minigels with MOPS (morpholinepropanesulfonic acid) running buffer
(Life Technologies). Following electroblotting onto polyvinylidene diflu-
oride membranes (Life Technologies) and blocking in 5% fat-free milk
and 1% Tween 20 in phosphate-buffered saline, pH 7.2, the membranes
were incubated with primary antibodies overnight at 4°C. The antibodies
to Oct-1 (antibody C-21), Oct-2 (antibody C-20), Zeb1 (antibody
H-102), and Zeb2 (antibody H-260) were all used at 1g/ml, and calregu-
lin antibody was used at 0.2 g/ml (Santa Cruz Biotechnology). The an-
tibodies to Notch-1 (antibody D3B8), Notch-2 (antibody D76A6),
Notch-3 (antibody 8G5), and Notch-4 (antibody L5C5) (Cell Signaling
Technology) were all used at a dilution of 1/1,000. The HLA class I anti-
body (HC10) was used at a dilution of 1/1,000 (36), and the histone H3
antibody (pS10; Life Technologies) was used at a dilution of 1/1,000.
Positive controls consisted of Notch-1 in Jurkat cells, Notch-2 in 293 cells,
Notch-3 in K562 cells, and Notch-4 in Jurkat cells.
Isolation of nuclei. Nuclei were isolated using a Nuclei EZ Prep nu-
cleus isolation kit (Sigma) according to the manufacturer’s protocol. The
numbers of whole cells and nuclei were recorded to ensure that exactly the
same numbers of cells used for the loading control were prepared for
Western blotting.
Inhibition and knockdown experiments. To inhibit Notch signaling,
EBV-infected B cells were incubated in culture medium with 5 M
-secretase inhibitor IX (Calbiochem) for from 24 h to 6 days. The me-
dium was replaced every 2 days with fresh inhibitor. Matched treated and
nontreated cells were harvested every 24 h, RNA was extracted, and pro-
tein samples were prepared for analysis of the downstream effects of in-
hibitor treatment.
Knockdown of Zeb2 expression in BNHL-1 cells was achieved us-
ing short hairpin (shRNA) lentiviral vectors. BNHL-1 cells were trans-
duced with lentivirus Zeb2 shRNA and lentivirus control shRNA
(Santa Cruz Biotechnology) according to the manufacturer’s instruc-
tions. Briefly, 0.25  106 cells were plated in complete medium con-
taining 5 g/ml Polybrene and 250 l lentivirus and incubated over-
night. To determine the transduction efficiency, control lentivirus
expressing GFP (Santa Cruz) was used exactly as described above, and
the cells were analyzed by flow cytometry after 24 h incubation. Cells
were harvested every 2 days postransduction and assayed for Zeb2
knockdown by Western blotting.
RESULTS
The initial set of experiments was performed on the BNHL-1 cell
line, cells of which were established and maintained on mouse
thymic stromal cells expressing the human Notch ligand Delta-
like ligand 1 (OP9-DLL1 cells). Serendipitously, when these cells
were experimentally infected with EBV, they revealed remarkable
Notch-dependent regulation of viral gene expression.
EBV-infected BNHL-1 cells adopt a strict latency I pheno-
typewhengrownonOP9 stromal cells expressinghumanDelta-
like ligand 1. At day 8 following explantation of patient bone
marrow-derived cells onto OP9-DLL1 stroma, the BNHL-1 cells
were infected with recombinant EBV Akata. More than 50% of the
lymphoma cells were infected, as judged by the expression of GFP
(Fig. 1A). Following cell sorting into GFP-positive and GFP-neg-
ative B cell populations, measurement of the EBV genome load by
qPCR confirmed EBV infection with approximately 130 genomes
per cell in only the GFP-positive cells (Fig. 1B).
Examination of EBV gene transcription in the BNHL-1 cells
revealed a pattern of expression that was consistent with a re-
stricted latency I rather than the latency III that is characteristi-
cally observed in the LCLs established following infection of nor-
mal primary B cells. Thus, we observed EBNA1 transcription, plus
that of the EBER and BART genes, only from the Q promoter (Qp)
across the Q-U-K splice; expression of other latent genes was sup-
pressed, as was expression of the BZLF1 immediate early lytic cycle
gene (Fig. 1C, top). This form of EBV gene expression was quite
distinct from latency III, or the growth transformation program,
that is observed in normal LCLs (Fig. 1C, bottom). In LCLs, EBNA
transcription is initially driven from the W promoter (Wp) and
then switches to the C promoter (Cp), allowing expression of all 6
EBNA genes. In this Wp/Cp form of latency, known as latency III,
the EBNA1 transcripts are generated via the Y-U-K splice, as op-
posed to the Q-U-K splice observed in latency I. In addition to the
complete repertoire of EBNAs, latency III is associated with
EBNA2-induced expression of the LMP1 and LMP2A transcripts
that were repressed in the EBV-infected BNHL-1 cells.
Removal fromOP9-DLL1 stromal cells triggers the EBV lytic
cycle in BNHL-1 cells. The restricted pattern of latent EBV gene
expression in newly infected BNHL-1 B cells was unexpected,
since EBV-negative Burkitt lymphoma (BL) lines typically initially
establish a latency III pattern of gene expression when experimen-
tally infected with EBV, in contrast to the latency I pattern char-
acteristically displayed by tumor cell lines derived from EBV-pos-
itive BL biopsy specimens. However, following extended culture,
latency I can be established in a subset of BL clones (37). We
hypothesized that coculture of BNHL-1 cells with stromal cells
might be modulating viral gene expression. To test this possibility,
the infected BNHL-1 cells were removed from the OP9-DLL1 cells
and aliquots were harvested daily thereafter to determine if the
pattern of EBV gene expression changed. In fact, the pattern of
latent gene expression was essentially unchanged following re-
moval of BNHL-1 cells from the OP9-DLL1 stroma (data not
shown). Remarkably, however, removal of DLL1/Notch signaling
led to a striking disruption of latency with induction of BZLF1 and
the lytic cycle. Figure 2A shows the results of qRT-PCR assays of
BZLF1 mRNA transcription over 6 days following removal from
OP9-DLL1 cells. The level of BZLF1 transcription in EBV-positive
BNHL-1 cells was compared to the level of BZLF1 mRNA ob-
served in Akata cells at 12 h following induction of the lytic cycle
Counteracting Effects of Notch and EBV EBNA2
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by ligation of its B cell receptor. BZLF1 mRNA levels increased
rapidly from 3 days onwards to 70% of the levels observed in Akata
BL cells induced into the lytic cycle. This induction of the lytic
cycle in infected BNHL-1 cells following removal of stromal inter-
actions was confirmed by immunoblotting for BZLF1 protein
(Fig. 2B) and by single-cell immunofluorescence (Fig. 2C). In rep-
licate experiments, the proportion of infected BNHL-1 cells ex-
pressing BZLF1 by day 6 ranged from 20% to 40%. Interestingly,
the induction of the lytic cycle in the BNHL-1 cells removed from
OP9-DLL1 stromal cells progressed efficiently to virus produc-
tion, as shown by the immunofluorescence for capsid protein and
gp350 (Fig. 2C), with at least half of the cells that initiated lytic
replication expressing these late viral structural genes.
BZLF1 expression following removal from the OP9-DLL1 cells
was presumed to result from the removal of DLL1/Notch signal-
ing. To discount the possibility that other cytokines released from
the OP9-DLL1 cells might be modulating EBV gene expression,
we first removed the infected BNHL-1 cells from the OP9-DLL1
cells and cultured them either in conditioned medium from the
OP9-DLL1 cells or in fresh medium and then compared the levels
of BZLF1 mRNA transcription. We found no difference in either
the rate of cell growth or the level of BZLF1 expression between
cells in fresh and conditioned medium (data not shown). We then
examined whether BZLF1 transcription was regulated by contact
with stromal cells or by the Delta-like ligand 1. We therefore com-
pared EBV gene transcription in BNHL-1 cells cocultured with the
OP9-DLL1 cells or with control OP9-GFP stromal cells or cul-
FIG 1 Generation of a BNHL-1 cell line with a strict latency I phenotype. (A)
Photomicrograph of EBV-infected (GFP-positive) and uninfected (GFP-neg-
ative) BNHL-1 cells cocultured on mouse thymic stromal cells expressing the
human Delta-like ligand 1 (OP9-DLL1 cells). (B) EBV load of GFP-positive
(POS) and GFP-negative (NEG) BNHL-1 cells compared to EBV load of six
individual LCLs. The results of assays performed in triplicate are shown. (C)
Quantitation of relative levels of EBV mRNA transcripts by qRT-PCR in LCLs
(top) and BNHL-1 cells (bottom) cocultured with OP9-DLL1 cells. The histo-
grams show for each EBV transcript the amount of mRNA transcripts relative
to that for a suitable reference cell line, which was given an arbitrary value of 1.
FIG 2 Removal of EBV-infected BNHL-1 cells from the OP9-DLL1 stromal
cells triggers the EBV lytic cycle. (A) Quantitation of relative levels of EBV
BZLF1 mRNA transcripts by qRT-PCR in EBV-infected BNHL-1 cells cul-
tured on or off OP9-DLL1 stromal cells. An example graph of the level of
expression of BZLF1 transcripts normalized to that in lytic Akata BL cells as the
reference cell line is shown. Each assay was performed in triplicate. d, day. (B)
Western blot analysis of BZLF1 expression in BNHL-1 cells following removal
from OP9-DLL1 stromal cells probed with a BZLF1-specific monoclonal an-
tibody (BZ1). (C) Single-cell immunofluorescence of BNHL-1 cells 6 days
after removal from OP9-DLL1 stromal cells. The cells were probed with anti-
bodies for both immediate early (BZLF1) and late (minor capsid protein
gp350) lytic cycle proteins, revealing that 20 to 40% of cells removed from
OP9-DLL1 stromal cells entered the lytic cycle.
Rowe et al.
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tured off stroma. We found that BZLF1 mRNA transcription was
inhibited only when the cells were cocultured on OP9-DLL1 cells;
when the cells were cocultured with OP9-GFP cells, BZLF1 tran-
scription was initiated at the same rate seen when the cells where
removed from the stroma (data not shown).
BZLF1 expression is regulated by Notch-2 ligation. The
aforementioned experiments strongly implicated Delta-like li-
gand 1 as an inhibitor of BZLF1 expression. Given that Delta-like
ligand 1 is a pan-Notch ligand, we then asked which Notch on the
BNHL-1 cell surface was interacting with DLL1 mediating the
signal transduction. Western blotting analyses for intracellular
Notch-1 (ICN-1), ICN-2, ICN-3, and ICN-4 were performed on
the infected BNHL-1 cells during OP9-DLL1 cell coculture and
following removal from OP9-DLL1 cells (Fig. 3A). These experi-
ments showed that ICN-1 and ICN-3 were poorly or not detected
in BNHL-1 cells, while ICN-4 was detected at high levels through-
out the time course, suggesting constitutive activation. However,
ICN-2 was detected only when cocultured with OP9-DLL1 cells
(day 0). Within 24 h of removal from the OP9-DLL1 cells, the level
of ICN-2 had decreased to almost undetectable levels. These data
show that BNHL-1 Notch-2 is ligated by DLL1 on the stromal cell
surface and that removal of the BNHL-1 cells from the stromal
cells abolished Notch-2 signaling.
To formally confirm that Notch was activated, the BNHL-1
cells were cocultured with OP9-DLL1 cells or removed from OP9-
DLL1 cells for 6 days. The nuclei were isolated from the cocultured
cells and every day following removal from OP9-DLL1 cells. West-
ern blot analysis was performed on whole-cell lysates and nuclear
lysates, with equal numbers of cells being added to each lane. The
blots were probed for Notch to ensure that it was detectable only
when cells were cocultured; for HLA class I, which is not found in
the nucleus; and for histone H3, which is found only in the nu-
cleus. The results confirmed that activated (nuclear) Notch2 is
detected only in the nucleus when the BNHL-1 cell line is cocul-
tured with OP9-DLL1 cells.
To confirm that BZLF1 was being regulated by Notch-2 liga-
tion, the BNHL-1 cells on OP9-DLL1 cells were treated with an
inhibitor of -secretase, the enzyme which cleaves Notch on the
plasma membrane and releases ICN to translocate to the nucleus.
The BNHL-1 cells were cocultured with OP9-DLL1 cells and
FIG 3 Notch-2 regulates entry into the lytic cycle. (A) Western blot analysis of BNHL-1 cells cocultured with OP9-DLL1 stromal cells (day 0) or cultured for up
to 5 days following removal from the OP9-DLL1 cells. Each blot was probed with antibodies to truncated intracellular (IC) Notch-1, -2, -3, or -4. Intracellular
Notch-2 was observed when it was ligated by DLL1, but its levels rapidly dropped by 24 h following its removal. Positive controls consisted of Notch-1 in Jurkat
cells, Notch-2 in 293 cells, Notch-3 in K562 cells, and Notch-4 in Jurkat cells.C, positive control. (B) Western blot analysis of whole-cell lysates and nuclei of
BNHL-1 cells cultured on and off OP9-DLL1 cells. The blot was probed for ICN-2 for detection of activated Notch-2, HLA class I for detection of plasma
membrane components, and for histone H3 for detection of components of the nuclei only. This shows that activated Notch is present only in the nucleus of cells
during cocultivation of BNHL-1 cells on OP9-DLL1 cells. (C) Quantitation of relative levels of BZLF1 mRNA transcripts in BNHL-1 cells cocultured with
OP9-DLL1 stromal cells, OP9-GFP stromal cells, and OP9-DLL1 stromal cells with a -secretase (-Sec) inhibitor to inhibit the cleavage of Notch into the
activated intracellular Notch. Inhibition of Notch activation by the -secretase inhibitor resulted in the induction BZLF1. Each assay was performed in triplicate.
(D) Western blot analysis of BNHL-1 cells cocultured on OP9-DLL1 cells and treated with the -secretase inhibitor. The blots were probed with antibodies to
BZLF1 and Notch-2. BZLF1 was expressed following treatment (Tx) with the -secretase inhibitor (GSI) (top), and inhibitor treatment resulted in undetectable
intracellular Notch-2 (bottom).
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treated with the -secretase inhibitor on day 0 and then subse-
quently every 2 days for 6 days. Cell aliquots were harvested daily
for extraction of RNA and protein. Figures 3B and C show the
results of qRT-PCR and Western blot analysis. In the -secretase
inhibitor-treated cells, BZLF1 transcription was observed from
day 1 posttreatment and increased over the 6 days (Fig. 3C). Sim-
ilarly, the BZLF1 protein was observed from day 1 posttreatment
by Western blotting (Fig. 3D, top). Importantly, a Western blot
assay for ICN-2 performed on the same cells confirmed that the
cleavage of Notch-2 was inhibited by treatment with the inhibitor
of -secretase (Fig. 3D, bottom). These data confirm that BZLF1
expression is regulated by Notch-2 ligation.
Zeb2 is regulated by Notch-2 ligation. To determine how
Notch inhibits BZLF1, we examined whether known regulators of
BZLF1 or BRLF1 were themselves regulated by Notch. In the first
instance, we examined Oct-1 and Oct-2. Oct-1 binds to the
BRLF-1 promoter to induce BRLF1 transcription and the subse-
quent lytic cycle (38). Conversely, Oct-2 binds to the BZLF1 pro-
tein and inhibits the lytic cycle (39). To determine if Oct-1 and
Oct-2 are regulated by Notch ligation, we examined their mRNA
(Fig. 4A) and protein (Fig. 4B) expression levels in BNHL-1 cells
over a 6-day period following removal from OP9-DLL1 cells and
in -secretase inhibitor-treated BNHL-1 cells on OP9-DLL1 cells.
No difference in the transcription of Oct-1 mRNA in BNHL-1
cells off OP9-DLL1 cells or following inhibition by-secretase was
observed (Fig. 4A, first graph). Furthermore, the concentration of
Oct-1 protein remained constant over the entire time course (Fig.
4B, top). While the level of transcription of Oct-2 mRNA in
BNHL-1 cells decreased by up to 2-fold following removal from
OP9-DLL1 cells, this reduction was not reflected in BNHL-1 cells
remaining on OP9-DLL1 cells but treated with the -secretase
inhibitor, which suggests that the effect of stroma on Oct-2 mRNA
expression in BNHL-1 cells is not specific to the DLL1-Notch
interaction (Fig. 4A, second graph). Furthermore, the levels of the
Oct-2 protein were unchanged (Fig. 4B, second panel). Together,
these data suggest that neither Oct-1 nor Oct-2 is directly regu-
lated by Notch ligation.
Next, we examined Zeb1 and Zeb2, both of which are reported
to interact with the BZLF1 promoter and inhibit the lytic cycle in
model systems (40). As described above, we examined the expres-
sion of Zeb1 and Zeb2 mRNA and protein expression levels in
BNHL-1 cells off OP9-DLL1 cells or in BNHL-1 cells on OP9-
DLL1 cells but treated with the -secretase inhibitor. Little differ-
ence in the transcription of Zeb1 mRNA in BNHL-1 cells off OP9-
DLL1 cells or following inhibition of -secretase was apparent
(Fig. 4A, third panel), and the concentration of Zeb1 protein re-
mained constant (Fig. 4B, third graph). In marked contrast, the
transcription of Zeb2 mRNA was reduced by up to 6-fold follow-
ing removal from OP9-DLL1 cells and similarly following inhibi-
tion of -secretase while on OP9-DLL1 stroma (Fig. 4A, fourth
graph). Furthermore, the effect on Zeb2 mRNA was paralleled by
a reduction in the levels of Zeb2 protein detected by Western
blotting (Fig. 4B, bottom). This strongly suggests that Zeb2 is
regulated by Notch ligation.
To confirm that Zeb2 was regulating the expression of BZLF1
in this system, we performed Zeb2 knockdown experiments in
BNHL-1 cells during coculture with OP9-DLL1 cells. Using a len-
tivirus shRNA construct containing 3 target-specific constructs or
FIG 4 Zeb2 is regulated by Notch ligation. (A and B) Analysis of Oct-1, Oct-2, Zeb1, and Zeb2 expression in BNHL-1 cells by quantitation of relative levels and
Western blotting. (A) BNHL-1 cells were either removed from OP9-DLL1 stromal cells (black line) or cocultured on OP9-DLL1 stromal cells with a -secretase
inhibitor (gray line). Only the levels of the Zeb2 mRNA transcripts were reduced following removal from stromal cells and following -secretase inhibitor
treatment. Each assay was performed in triplicate. (B) The findings described for panel A are also reflected in protein levels, where only the Zeb2 protein levels
were reduced following removal from stromal cells (or -secretase inhibitor treatment; not shown). (C) Zeb2 knockdown by shRNA. BNHL-1 cells were
transduced by lentiviruses expressing shRNA to knock down the levels of Zeb2 expression or scrambled shRNA and maintained on OP9-DLL1 stromal cells. (Top
two panels) Zeb2 knockdown in the presence of Notch ligation; (fourth panel) Zeb2 following transduction with scrambled shRNA. (D) Quantitation of relative
levels of BZLF1 mRNA and protein in BNHL-1 cells maintained on OP9-DLL1 stromal cells following Zeb2 knockdown. BZLF1 is expressed in the absence of
Zeb2.
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a control lentivirus containing a scrambled shRNA sequence, we
transduced the BNHL-1 cells with each of the lentiviruses while
the BNHL-1 cells remained on OP9-DLL1 cells to ensure that
Notch ligation was still intact during the knockdown. Figure 4C
shows Western blots for Zeb2 of BNHL-1 cells transduced with
the Zeb2 shRNA or the control scrambled shRNA. The level of
Zeb2 protein on days 2 and 4 postinfection decreased by up to
70% compared to that for cells transduced with the scrambled
shRNA control. On the same cells, the unaltered presence of
ICN-2 was confirmed (Fig. 4C). Having confirmed the successful
knockdown of Zeb2, we asked if Zeb2 was responsible for the
inhibition of BZLF1 transcription. As shown in Fig. 4D, in the
presence of ICN-2, the knockdown of Zeb2 induced the transcrip-
tion of BZLF1. Together, the data in Fig. 4 indicate that Notch
ligation upregulates Zeb2, which itself directly represses BZLF1.
Notch ligation inhibits virus BZLF1 expression in primary B
cell infection.We next wanted to examine if Notch ligation would
inhibit the expression of BZLF1 in a primary B cell infection. We
infected newly isolated resting B cells with wild-type virus and
immediately cocultured the B cells on the OP9-DLL1 cells or the
control OP9-GFP cells. Figure 5A represents the results of qRT-
PCR of BZLF1 mRNA transcription for four independent B cell
infection experiments over 7 days postinfection. A very low level
of BZLF1 mRNA transcription was detected in cells cocultured on
the OP9-GFP cells, which is typical of what we normally observe in
B cell infection experiments, but was not detected in cells cocul-
tured on the OP9-DLL1 cells. In extended experiments of up to 30
days, BZLF1 inhibition was maintained (data not shown). How-
ever, if an established LCL with a small but defined level of BZLF1
expression was cocultured with the OP9-DLL1 cells, the BZLF1
was not switched off (data not shown), suggesting that the viral
genome had already been epigenetically altered in such a way that
could not be undone by Notch ligation.
As BZLF1 expression in BNHL-1 cells followed the downregu-
lation Zeb2 expression after the removal of Notch ligation, we
asked if Zeb2 is involved in BZLF1 inhibition in primary B cell
infection. Contrary to our expectations, we found that the tran-
scription of both Zeb1 and Zeb2 mRNA was rapidly downregu-
lated in the newly infected B cells, irrespective of whether or not
they were cocultured on the OP9-DLL1 cells (Fig. 5B and C). One
possible explanation for this anomaly is that the amount of BZLF1
transcription observed in primary infection was so low that it
could have been due to less than 0.2% of cells expressing BZLF1.
In such a scenario, measurement of Zeb1 and Zeb2 expression in
the total population is uninformative.
The major difference between infection of BNHL-1 cells and
infection of normal primary resting B cells is that primary B cells
go on to express the full growth transformation program of EBV
genes (i.e., latency III). We reasoned that an EBV gene expressed
early following infection may be responsible for the rapid down-
regulation of Zeb2 following infection. Since both EBNA2 and
Notch function through RBP-J, we examined Zeb1 and Zeb2
expression in primary resting B cells infected with virus with an
EBNA2 deletion. As shown in Fig. 5D, we observed that Zeb2
mRNA transcription was maintained in B cells infected with virus
with an EBNA2 deletion. Exactly the same observation was made
for Zeb1 mRNA transcripts (not shown). This suggests that
EBNA2 may play a role in inhibiting Zeb2 expression, even in the
presence of Notch ligation.
Notch ligation inhibits LMP1 expression. EBNA2 is one of
the first latent proteins to be expressed during infection of normal
B cells and is an important transcriptional regulator of other latent
EBV genes. Given the previously reported interrelationships be-
tween EBNA2 and Notch signaling pathways, we therefore que-
ried whether Notch ligation might modulate the pattern of latent
gene expression during primary infection. We performed qRT-
PCR for the EBV genes expressed during infection of resting B
cells cocultured on OP9-DLL1 or OP9-GFP stromal cells or in
suspension. Figure 6A shows representative examples of the tran-
scription of mRNA for the latency III-associated growth-trans-
forming EBV genes. Transcription from the Wp and Cp promot-
ers, including the transcription of EBNA1 and EBNA2, was
unaffected by Notch ligation. However, the levels of LMP1 mRNA
were consistently more than 5-fold lower when the B cells were
cocultured on OP9-DLL1 cells. Similarly, the levels of LMP2a
mRNA were at least 2- to 3-fold lower on OP9-DLL1 cells.
LMP1 is regulated by two promoters: the classical ED-L1 pro-
moter containing an EBNA2-regulated element and a second pro-
moter, LT-R1, within the terminal repeat (TR) region of the EBV
genome that lacks this regulatory element. During primary B cell
infection in vitro, the predominant promoter used for LMP1 ex-
pression is the classical EBNA2-regulated promoter. We therefore
examined which LMP1 promoter was being used and which was
FIG 5 Notch ligation inhibits BZLF1 in primary B cell infection. (A) Quanti-
tation of relative levels of BZLF1 mRNA expression in primary B cell infection.
Primary resting B cells were infected and cocultured on and off OP9-DLL1
stromal cells. The cells cultured off stroma or on OP9-GFP stromal cells ex-
pressed a very small amount of BZLF1 transcripts, which were inhibited when
the B cells were cultured on OP9-DLL1 stromal cells. WT, wild type. (B and C)
Quantitation of relative levels of Zeb1 and Zeb2 mRNA transcripts in primary
B cell infection on and off OP9-DLL1 stroma. The levels of the Zeb1 and Zeb2
mRNA transcripts dropped rapidly both in the presence and in the absence of
the Notch ligand, albeit the rate of drop of Zeb2 was lower in the presence of
the Notch ligand. (D) Quantitation of relative levels of Zeb2 mRNA transcripts
in primary B cell infection with recombinant wild-type EBV and EBV with an
EBNA2 deletion (EBNA2 knockout [E2KO]) off OP9-DLL1 stromal cells. The
Zeb2 mRNA transcript levels did not drop in cells infected with the virus with
the EBNA2 deletion compared to the levels in cells infected with wild-type
virus. The same was observed when the cells were cultured on OP9-DLL1 cells.
Each assay was performed in triplicate on three biological replicates. Repre-
sentative plots are shown.
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being inhibited by Notch ligation during primary B cell infection.
To this end, we quantitated the relative number of LMP1 mRNA
transcripts using two different assays and a uniform standard; one
assay measured the total number of LMP1 transcripts from either
promoter, and a second measured only the number of LMP1 tran-
scripts from the LT-R1 promoter within the TR. Figure 6B shows
the results of one representative assay of three replicate experi-
ments. By day 6 postinfection, the total number of LMP1 mRNA
transcripts was reduced from 0.28 transcript per B2M transcript
when cells were cocultured on OP9-GFP cells to 0.042 transcript
per B2M transcript when cells were cocultured on OP9-DLL1
cells. Interestingly, the number of transcripts of LMP1 derived
from the promoter in the TR increased to an average of 0.01 per
B2M transcript by day 6 postinfection. These results suggest that
Notch ligation strongly inhibits the transcription of LMP1 mRNA
originating from the ED-L1 promoter containing the EBNA2-reg-
ulated element.
Given that Notch ligation inhibits ED-L1-driven LMP1 tran-
scription during primary cell infection, we asked if Notch ligation
could switch off LMP1 transcription once the B cells have trans-
formed into LCLs. We therefore cocultured established LCLs with
OP9-DLL1 cells or with the control OP9-GFP cells and examined
LMP1 transcription daily. Figure 7A shows the relative quantita-
tion of total LMP1 mRNA transcripts and TR-derived LMP1
mRNA transcripts over 21 days of coculture on OP9-DLL1 cells.
Remarkably, a 30-fold reduction in total LMP1 mRNA levels was
observed within 24 h of DLL1 exposure (Fig. 7A), but no such
decrease was observed when the LCL was cocultured with OP9-
GFP cells (not shown). Interestingly, there was a corresponding
increase in the amount of TR-derived LMP1 transcripts, to the
extent that most of the LMP1 transcripts in the LCL cells grown on
OP9-DLL1 were probably derived from the TR promoter instead
of the classical EBNA2-regulated LMP1 promoter. The drop in
total LMP1 transcripts was mirrored by a drop in LMP1 protein
levels (Fig. 7B), which was maintained for at least 21 days (data not
shown). However, LMP1 protein levels rapidly rebounded to the
levels observed without Notch ligation if the B cells lost contact
with the OP9-DLL1 cells, which was observed on day 6. Examina-
tion of the LMP2A and EBNA2 proteins (Fig. 7B) and transcripts
(not shown) following coculture with OP9-DLL1 cells showed an
initial drop in LMP2a expression at day 2 which quickly recovered
to the levels observed when the cells were not cocultured with
OP9-DLL1 stroma.
FIG 6 Notch ligation inhibits LMP1 expression in primary B cell infection.
(A) Quantitation of relative levels of EBV latent gene transcripts. Primary B
cells were infected and cocultured on OP9-DLL1 stromal cells or on OP9-GFP
stromal cells. The graphs show an example of the normalized amounts of the
transcripts for each of the latent genes expressed early following primary B cell
infection. All infections were performed four times. (B) Quantitation of the
absolute amounts of LMP1 mRNA transcripts. qRT-PCR was performed for
total LMP1 or TR (LT-R1 promoter)-derived LMP1 mRNA transcripts, and
the amounts were compared with those of a serially diluted plasmid of known
copy number encoding the LMP1 amplicon sequences. Both graphs show
representative values for each LMP1 transcript either on OP9-DLL1 cells or on
OP9-GFP cells. All assays were performed in triplicate with three biological
replicates. Representative plots are shown. UI, uninfected.
FIG 7 Notch ligation inhibits LMP1 expression in LCLs. (A) Quantitation of absolute amounts of total LMP1 and TR (LT-R1 promoter)-derived LMP1 mRNA
transcripts in LCLs cocultured on OP9-DLL1 stromal cells. qRT-PCR was performed for total LMP1 and TR (LT-R1 promoter)-derived LMP1 mRNA
transcripts, and the amounts were compared with those of a serially diluted plasmid of known copy number encoding the LMP1 amplicons. The graph shows the
results of a representative assay of the time course of LCLs on stroma. The assay was performed in triplicate on four biological LCL replicates. (B) Western blot
analysis of LMP1 expression in LCLs cocultured on OP9-DLL1 stromal cells. The blots were probed with LMP1, LMP2a, and EBNA2 antibodies. The blots show
the inhibition of LMP1 expression, a temporal drop in LMP2a expression which rebounded by 4 days, and no change to EBNA2 expression. (C) Relative qPCR
of PU.1 and MYC in LCLs cocultured with OP9-DLL1 stromal cells. There was no change in mRNA transcripts following culture on OP9-DLL1 stromal cells.
Rowe et al.
12072 jvi.asm.org Journal of Virology
 o
n
 N
ovem
ber 18, 2014 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
Finally, we addressed whether the drop in LMP1 expression
was caused by the specific inhibition of EBNA2 induction of
LMP1 by Notch or if all EBNA2-regulated genes were affected. To
this end, we first examined whether other transcription factors
that regulate LMP1 expression from the classical promoter were
downregulated by Notch ligation. We performed a qRT-PCR as-
say for PU.1, a transcription factor essential for LMP1 expression,
which revealed that the level of mRNA transcripts remained
unaffected by Notch ligation compared to the effect of no liga-
tion (Fig. 7C). We also performed a qRT-PCR assay for Myc,
which is a specific downstream target of EBNA2, to confirm
that Notch ligation did not inhibit all downstream targets of
EBNA2 (Fig. 7C).
DISCUSSION
Little is known about the regulation of EBV gene expression fol-
lowing primary infection of resting B lymphocytes in vivo, partic-
ularly how EBV gene expression is downregulated from the la-
tency III gene expression profile to the latency 0 profile seen in
circulating resting memory B cells. Much of our understanding
about the regulation of individual viral genes has come from stud-
ies of cell lines. Although they are extremely informative, such
studies have limitations in that they do not necessarily take into
account signaling from the microenvironment in vivo, be it medi-
ated by contact with neighboring cells of different lineages or by
soluble factors released from these cells. With regard to soluble
factors, it has been shown by others that the T cell-derived cyto-
kines interleukin-21 (IL-21) and CD40L may downregulate
EBNA2 expression in latency III LCLs and that IL-4, IL-10, IL-13,
and IL-21 can induce LMP1 expression in certain malignant B cell
lines (41–44). In our study, we investigated the consequence of
Notch ligation in EBV-infected B cells and observed that while
DDL1/Notch-2 activation does not alter the expression of EBNA2,
it markedly inhibits the ability of EBNA2 to induce LMP1 and
LMP2a transcription during primary B cell infection and in estab-
lished LCLs. Furthermore, activation of Notch-2 also inhibits lytic
cycle induction through the upregulation of Zeb2 expression,
which represses the transcription of BZLF1.
The control of EBV latency and lytic reactivation in EBV is a
complex process involving a number of transcriptional activators
and repressors acting upon the immediate early transducers of
lytic cycle activation, BZLF1 (Zta) and BRLF1 (RTA). The master
regulator of the latent-lytic cycle switch, BZLF1, binds directly to
Zta response elements throughout the viral genome and activates
both early and late lytic cycle genes (45). BZLF1 does not rely on
DNA binding proteins, such as RBP-J, to activate the promoters
of the lytic cycle genes, so it is not regulated by Notch at this level.
Four transcription factors have previously been shown to regulate
BZLF1 and BRLF1 either positively or negatively; these include
Zeb1 and Zeb2 (40, 46–48) and Oct-1 and Oct-2 (38, 39). The
Zeb1 and Zeb2 transcription factors inhibit lytic cycle reactivation
by repression of BZLF1 transcription; both Zeb1 and Zeb2 bind to
the ZV element-containing region of the Z promoter (Zp; the
BZLF1 promoter) and repress transcription initiated at Zp (40).
Oct-2 inhibits lytic cycle reactivation by directly interacting with
BZLF1, resulting in the attenuation of BZLF1 binding to lytic viral
promoters. Conversely, Oct-1 promotes viral lytic reactivation by
interacting with BRLF1 to enhance the interaction of BRLF1 with
viral lytic promoters. These transcription factors are not all func-
tional in the same cell lineage; indeed, their activities appear to be
cell type specific (38–40, 46–48). Our present work shows that
DLL1/Notch-2-mediated inhibition of BZLF1 expression in the
EBV-infected BNHL-1 cell line is mediated via the Notch-regu-
lated expression of the transcription factor Zeb2.
A role for Notch in the regulation of the virus lytic cycle has not
previously been described for EBV. In contrast, the lytic cycle of
Kaposi’s sarcoma-associated herpesvirus (KSHV) is known to be
regulated both positively and negatively by the Notch pathway,
although mechanistically the roles of Notch in regulating the EBV
and KSHV lytic cycle are quite distinct. The master regulator of
KSHV lytic cycle is the virally encoded RTA (ORF50), a transcrip-
tion factor which can stimulate the transcription of up to 80 lytic
genes (49). Although RTA can bind to a specific DNA sequence
found in a few viral promoters, for the most part RTA relies on
cellular coregulators, including RBP-J (CSL) (50), C/EBP (51,
52), Oct-1 (53), and c-Jun (54), to bind to DNA. For instance,
RTA forms a complex with RBP-J and binds to RTA-responsive
promoters with RBP-J binding sites, recruits coactivators
through its own C-terminal activation domain, and activates tran-
scription of that gene. In some cases this is directly influenced by
cell surface Notch ligation, as is the case for K2 and K5 (55).
Our observations on the control of EBV lytic cycle entry in the
infected BNHL-1 lymphoma cell model provide novel insight into
the regulation of lytic cycle induction by extracellular signals. We
also observed that Notch-2 ligation inhibited the very low levels of
BZLF1 transcription that occur during in vitro infection of pri-
mary B cells. However, the effect of this small but reproducible
effect warrants closer examination to determine its significance. Un-
expectedly, in contrast to the findings presented in one previously
published report (37), we found that EBV infection itself caused a
substantial downregulation of Zeb2 expression which was probably
EBNA2 dependent and was apparently not reversed by Notch liga-
tion. This indicates that the downregulation of Zeb2, even if neces-
sary, is not by itself sufficient to induce BZLF1 expression. It is not
clear by what mechanism Notch-2 activation inhibits what little
BZLF1 transcription does occur. As the amount of BZLF1 mRNA
detected is equivalent to that from less than 0.5% of cells entering the
lytic cycle, it is possible that Notch-2 activation may be upregulating
Zeb2 expression in a relevant subset of cells able to transcribe BZLF1;
alternatively, Notch-2 activation may be acting via a different mech-
anism in primary infection of normal B cells.
A more pronounced consequence of Notch activation during
infection of normal B cells and in established LCLs was that it
inhibited the de novo expression of LMP1 in the primary infection
and switched off LMP1 expression in established LCLs already
expressing LMP1. One explanation for this observation suggests
that the interaction of ICN-2 with RBP-J blocks the interaction
of EBNA2 with RBP-J, thereby inhibiting the initiation of LMP1
transcription from the classical LMP1 promoter, which is EBNA2
responsive (56). In support of this hypothesis, quantitative PCR
assays revealed that the residual LMP1 expression in the pres-
ence of Notch activation was actually initiated from the LMP1
promoter within the terminal repeats, which is not EBNA2
responsive.
Similarly, Notch ligation also inhibits de novo LMP2a tran-
scription during primary B cell infection and downregulates
LMP2a expression in an established LCL. Like LMP1, the pro-
moter for LMP2a is also EBNA2 responsive (16), suggesting that
expression should remain low if LMP2a behaves like LMP1 fol-
lowing Notch ligation. However, unlike LMP1 transcription and
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expression in Notch-activated LCLs, the inhibition of LMP2a was
transient and transcription and expression subsequently recov-
ered to the levels observed without Notch ligation. This observa-
tion suggests either that LMP2a is not regulated by Notch or that
EBNA2 overrides this signal. However, LMP2a is often detected in
the absence of EBNA2 in B cell lymphomas, such as Hodgkin’s
lymphoma. LMP2a has been demonstrated to induce its own pro-
moter, and several reports have demonstrated that LMP2a consti-
tutively activates the Notch pathway (57–59). Furthermore, ICN
can bind to and activate the LMP2a promoter (60), and deletion of
the RBP-J consensus sequences results in a significant decrease in
LMP2a promoter activity (57). LMP2a therefore appears to utilize
the Notch pathway to induce its own expression in the absence of
EBNA2, which offers an explanation for why Notch activation has
subtly different effects on LMP1 and LMP2a expression.
If LMP2a is indeed constitutively activating the Notch pathway to
induce its own expression in Hodgkin’s lymphoma, our results would
suggest that either LMP1 expression in these cells would be inhibited
or LMP1 expression would be initiated at the terminal repeat pro-
moter. However, the promoter origin of LMP1 expression in Hodg-
kin’s lymphoma does not appear to have been elucidated. One study
identified TR-derived LMP1 transcripts in 10 out of 12 cases of Hodg-
kin’s lymphoma, albeit with concurrent expression from the classical
promoter (61). However, these assays were performed on total RNA
extracted from Hodgkin’s lymphoma biopsy specimens using end-
point PCR, thereby clouding the issue.
This study has extended the possible mechanisms by which
EBV-infected B cells in normal lymphoid tissues might be pre-
vented from activating lytic virus replication and switching off
growth transformation-associated latent viral genes during the
process of establishing latency 0 in nonproliferating memory B
cells. Previous studies (43, 44) identified a potential and signifi-
cant role for T cell-derived cytokines and soluble CD40 ligand in
downregulating the expression of EBNA2, albeit with a concomi-
tant upregulation of LMP1. To that body of work, we now add the
potential of stromal cell interactions to dramatically modulate
viral gene expression. The effects of DDL1-mediated Notch-2 ac-
tivation in infected B cells are remarkable and include interference
with EBNA2 function, the transcriptional downregulation of
LMP1 and LMP2, and the inhibition of lytic virus replication
through the prevention of BZLF1 induction. We consider it likely
that there will be additional, yet to be identified stromal interac-
tions which modulate viral gene function or expression. The next
challenge will be to delineate which of the many possible extracel-
lular signaling events are actually crucial for the normal process of
establishing the latency 0 state in memory B cells and how the
various cellular interactions at different microanatomical sites in
the lymphoepithelial tissue might enable reactivation of lytic virus
replication for secretion into the oropharynx.
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